Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2Sign in
← Cases

AKT3

RBC: AKT3 · Substrate: Crosstide ·

Top inhibitors

MeasuredDerived
DrugInhibition %Gini
Capivasertib98.50.64
Netarsudil69.20.68
Midostaurin39.90.50
Leniolisib27.40.60
Umbralisib25.90.67
Selumetinib25.50.64
Ponatinib21.20.53
Tenalisib17.50.70
Baricitinib16.70.62
Ceritinib16.10.62
Infigratinib13.50.71
Apatinib13.30.70
Paxalisib11.40.61
Darovasertib11.20.72
Pacritinib9.60.45

Known variants

Cancer associations

MutationCancer typeOrganSource
E17Kmalignant_melanoma_skinSkinhttps://doi.org/10.1093/nar/gkaa945
E17Kcarcinoma_lungLunghttps://doi.org/10.1093/nar/gkaa945
E17Kmalignant_melanoma_NSSkinhttps://doi.org/10.1093/nar/gkaa945
E17Kcarcinoma_prostateProstatehttps://doi.org/10.1093/nar/gkaa945
E17Kcarcinoma_thyroidThyroidhttps://doi.org/10.1093/nar/gkaa945
E17Kleiomyosarcoma_soft_tissueSoft Tissuehttps://doi.org/10.1093/nar/gkaa945
E17Kcarcinoma_penisGenitourinary systemhttps://doi.org/10.1093/nar/gkaa945
E17Kcarcinoma_kidneyKidneyhttps://doi.org/10.1093/nar/gkaa945
E17KKIRC-USKidneyhttps://doi.org/10.1093/nar/gkaa945
E17KLUSC-USLunghttps://doi.org/10.1093/nar/gkaa945
E17KPBCA-DEPancreashttps://doi.org/10.1093/nar/gkaa945
E17KSKCM-USSkinhttps://doi.org/10.1093/nar/gkaa945
E17KKIRCKidneyhttps://doi.org/10.1093/nar/gkaa945
E17KLUSCLunghttps://doi.org/10.1093/nar/gkaa945
E17KSKCMSkinhttps://doi.org/10.1093/nar/gkaa945
G171Rglioma_central_nervous_systemBrain/CNShttps://doi.org/10.1093/nar/gkaa945
Open in new tab